PL2872147T3 - Sposób wytwarzania chiralnych oligonukleotydów - Google Patents

Sposób wytwarzania chiralnych oligonukleotydów

Info

Publication number: PL2872147T3
Authority: PL; Poland
Prior art keywords: making chiral; chiral oligonucleotides; oligonucleotides; making; chiral
Prior art date: 2012-07-13

Application number

PL13817244.0T

Other languages

English (en)

Inventor

David Butler

Naoki Iwamoto

Meena Meena

Nenad Svrzikapa

Gregory L. Verdine

Ivan Zlatev

Original Assignee

Wave Life Sciences Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-13

Filing date

2013-07-12

Publication date

2023-09-25

2013-07-12 Application filed by Wave Life Sciences Ltd. filed Critical Wave Life Sciences Ltd.

2023-09-25 Publication of PL2872147T3 publication Critical patent/PL2872147T3/pl

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Massaging Devices (AREA)
Paper (AREA)
Extrusion Moulding Of Plastics Or The Like (AREA)

PL13817244.0T 2012-07-13 2013-07-12 Sposób wytwarzania chiralnych oligonukleotydów PL2872147T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261671656P	2012-07-13	2012-07-13
US201261671655P	2012-07-13	2012-07-13
US201261671724P	2012-07-14	2012-07-14
US201261671722P	2012-07-14	2012-07-14
PCT/US2013/050407 WO2014012081A2 (en)	2012-07-13	2013-07-12	Chiral control

Publications (1)

Publication Number	Publication Date
PL2872147T3 true PL2872147T3 (pl)	2023-09-25

Family

ID=49916709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13817244.0T PL2872147T3 (pl)	2012-07-13	2013-07-12	Sposób wytwarzania chiralnych oligonukleotydów

Country Status (17)

Country	Link
US (4)	US9982257B2 (pl)
EP (2)	EP2872147B1 (pl)
JP (3)	JP6453212B2 (pl)
KR (3)	KR102450907B1 (pl)
CN (2)	CN104661664B (pl)
AU (4)	AU2013289880B2 (pl)
CA (1)	CA2878945A1 (pl)
CL (1)	CL2015000092A1 (pl)
DK (1)	DK2872147T3 (pl)
ES (1)	ES2940887T3 (pl)
HK (1)	HK1210595A1 (pl)
IL (1)	IL236621B (pl)
MX (1)	MX2015000577A (pl)
PL (1)	PL2872147T3 (pl)
RU (1)	RU2015104762A (pl)
SG (3)	SG10201912895PA (pl)
WO (1)	WO2014012081A2 (pl)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2744987C (en)	2008-12-02	2018-01-16	Chiralgen, Ltd.	Method for the synthesis of phosphorus atom modified nucleic acids
WO2011005761A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc	Novel nucleic acid prodrugs and methods use thereof
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
BR112014001244A2 (pt)	2011-07-19	2017-02-21	Wave Life Sciences Pte Ltd	métodos para a síntese de ácidos nucléicos funcionalizados
US10273474B2 (en)	2012-03-30	2019-04-30	Washington University	Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
SG11201500243WA (en)	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
JP6268157B2 (ja)	2012-07-13	2018-01-24	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	不斉補助基
AU2013289880B2 (en)	2012-07-13	2018-08-02	Wave Life Sciences Ltd.	Chiral control
MX2015012621A (es)	2013-03-14	2016-05-31	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de tau.
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en)	2014-01-15	2018-12-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
DK3094728T3 (da)	2014-01-16	2022-05-16	Wave Life Sciences Ltd	Kiralt design
WO2015125845A1 (ja) *	2014-02-20	2015-08-27	塩野義製薬株式会社	含窒素非芳香族複素環を含む核酸のリン酸部位修飾
JP6543612B2 (ja) *	2014-03-04	2019-07-10	浩文山本	大腸癌の治療剤、及び大腸癌患者の予後の予測方法
US10619156B2 (en)	2014-05-28	2020-04-14	The Regents Of The University Of California	Hybrid tRNA/pre-miRNA molecules and methods of use
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
RU2708237C2 (ru)	2014-08-22	2019-12-05	Общество с ограниченной ответственностью "НооГен"	Модифицированные олигонуклеотиды и способ их получения
CA2963288A1 (en)	2014-10-03	2016-04-07	Cold Spring Harbor Laboratory	Targeted augmentation of nuclear gene output
JP2017536366A (ja) *	2014-11-19	2017-12-07	ロシュイノベーションセンターコペンハーゲンエーエス	Ｌｎａキラルホスホロチオエート
US10815481B2 (en)	2014-12-16	2020-10-27	Roche Innovation Center Copenhagen A/S	Chiral library screen
EP3712269A1 (en)	2014-12-17	2020-09-23	ProQR Therapeutics II B.V.	Targeted rna editing
MA43072A (fr) *	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
EP4285912A3 (en)	2015-09-25	2024-07-10	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating ataxin 3 expression
WO2017062862A2 (en) *	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
JP6923517B2 (ja)	2015-10-09	2021-08-18	ユニバーシティ・オブ・サザンプトン	遺伝子発現の調節及び脱制御されたタンパク質発現のスクリーニング
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
CN116059236A (zh)	2015-12-14	2023-05-05	冷泉港实验室	用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
JP6907939B2 (ja) *	2016-01-28	2021-07-21	東レ株式会社	癌の治療及び／又は予防用医薬組成物
AU2017234150B2 (en) *	2016-03-13	2021-09-16	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
WO2017157672A1 (en) *	2016-03-18	2017-09-21	Roche Innovation Center Copenhagen A/S	Acyl-protected l-lna-guanosine monomers
MA45471A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
MA45349A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques egfr et leurs utilisations
MA45470A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques kras et leurs utilisations
MA45469A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques de bêta-caténine et leurs utilisations
AU2017254106B2 (en)	2016-04-18	2024-07-11	Sarepta Therapeutics, Inc.	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2017190041A1 (en)	2016-04-29	2017-11-02	Sarepta Therapeutics, Inc.	Oligonucleotide analogues targeting human lmna
MA45270A (fr) *	2016-05-04	2017-11-09	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
DK3455232T3 (da) *	2016-05-12	2020-07-06	Roche Innovation Ct Copenhagen As	Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
US10882884B2 (en) *	2016-05-18	2021-01-05	Eth Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
JP2019520339A (ja) *	2016-06-03	2019-07-18	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド、その組成物および方法
MA45496A (fr)	2016-06-17	2019-04-24	Hoffmann La Roche	Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
AU2017281497B2 (en)	2016-06-22	2023-04-06	Proqr Therapeutics Ii B.V.	Single-stranded RNA-editing oligonucleotides
KR20190024977A (ko)	2016-06-30	2019-03-08	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머
US11981703B2 (en)	2016-08-17	2024-05-14	Sirius Therapeutics, Inc.	Polynucleotide constructs
NZ751483A (en)	2016-09-01	2022-07-01	Proqr Therapeutics Ii Bv	Chemically modified single-stranded rna-editing oligonucleotides
JOP20190065A1 (ar) *	2016-09-29	2019-03-28	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن tau
JOP20190104A1 (ar) *	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
MA46905A (fr)	2016-11-23	2019-10-02	Wave Life Sciences Ltd	Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
US20180193270A1 (en)	2016-11-29	2018-07-12	PureTech Health LLC	Exosomes for delivery of therapeutic agents
PL3554553T3 (pl)	2016-12-19	2022-11-07	Sarepta Therapeutics, Inc.	Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
MD3554552T2 (ro)	2016-12-19	2022-12-31	Sarepta Therapeutics Inc	Conjugați oligomeri de omitere a exonilor pentru distrofie musculară
RS65583B1 (sr)	2016-12-19	2024-06-28	Sarepta Therapeutics Inc	Oligomerni konjugati za preskakanje egzona za mišićnu distrofiju
KR20190104381A (ko)	2017-01-06	2019-09-09	어비디티 바이오사이언시스 엘엘씨	핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
EP3571300A1 (en)	2017-01-19	2019-11-27	ProQR Therapeutics II B.V.	Oligonucleotide complexes for use in rna editing
WO2018181428A1 (ja)	2017-03-29	2018-10-04	塩野義製薬株式会社	核酸医薬及び多分岐脂質の複合体
CN110475784B (zh) *	2017-03-29	2024-07-16	罗氏创新中心哥本哈根有限公司	用于制备立体限定硫代磷酸酯寡核苷酸的正交保护基
JP2020524485A (ja)	2017-06-02	2020-08-20	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
WO2018223073A1 (en) *	2017-06-02	2018-12-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
US11603532B2 (en)	2017-06-02	2023-03-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP7402696B2 (ja) *	2017-06-21	2023-12-21	ウェイブライフサイエンシズリミテッド	合成のための化合物、組成物、及び方法
US11814407B2 (en) *	2017-06-28	2023-11-14	Roche Innovation Center Copenhagen A/S	Multiple coupling and oxidation method
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
CA3072076A1 (en)	2017-08-08	2019-02-14	Chandra Vargeese	Oligonucleotide compositions and methods thereof
EP3673080B1 (en)	2017-08-25	2023-10-18	Stoke Therapeutics, Inc.	Antisense oligomers for treatment of conditions and diseases
SG11202000276YA (en) *	2017-09-18	2020-04-29	Wave Life Sciences Ltd	Technologies for oligonucleotide preparation
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019067979A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
WO2019067975A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
US20210145852A1 (en)	2017-09-28	2021-05-20	Sarepta Therapeutics, Inc.	Combination Therapies for Treating Muscular Dystrophy
JP2021500862A (ja)	2017-10-04	2021-01-14	アビディティーバイオサイエンシーズ，インク．	核酸ポリペプチド組成物およびその使用
JP2020537518A (ja)	2017-10-12	2020-12-24	ウェーブライフサイエンシーズリミテッド	オリゴヌクレオチド組成物及びその方法
US10953034B2 (en)	2017-10-16	2021-03-23	Hoffmann-La Roche Inc.	Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
WO2019079637A2 (en)	2017-10-18	2019-04-25	Sarepta Therapeutics, Inc.	ANTISENSE OLIGOMERIC COMPOUNDS
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
BR112020009092A2 (pt) *	2017-11-13	2020-10-20	Silence Therapeutics Gmbh	ácidos nucleicos para inibição da expressão de um gene alvo compreendendo ligações fosforoditioato
EP4328306A2 (en)	2017-12-01	2024-02-28	The Texas A&M University System	Angelman syndrome antisense treatment
AU2018378812A1 (en)	2017-12-06	2020-07-09	Avidity Biosciences, Inc.	Compositions and methods of treating muscle atrophy and myotonic dystrophy
CN108186564B (zh) *	2018-01-03	2020-06-02	上海市肿瘤研究所	一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用
WO2019152919A2 (en) *	2018-02-04	2019-08-08	The Texas A&M University System	Heterochiral nucleic acid strand-displacement systems and methods
SG11202008232QA (en) *	2018-03-14	2020-09-29	Hoffmann La Roche	Lna-dicarboxylic acid derivatives and process for their preparation
SG11202009877XA (en) *	2018-04-12	2020-11-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
SG11202010910QA (en)	2018-05-07	2020-12-30	Alnylam Pharmaceuticals Inc	Extrahepatic delivery
PE20212131A1 (es)	2018-05-09	2021-11-05	Ionis Pharmaceuticals Inc	Compuestos y metodos para reducir de la expresion de atxn3
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en)	2018-06-13	2022-06-22	Sarepta Therapeutics, Inc.	EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
PE20220013A1 (es)	2018-07-03	2022-01-11	Hoffmann La Roche	Oligonucleotidos para modular la expresion de tau
TW202020153A (zh)	2018-07-27	2020-06-01	美商薩羅塔治療公司	用於肌肉萎縮症之外顯子跳躍寡聚物
AU2019392928A1 (en) *	2018-12-06	2021-06-17	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
CN113412330A (zh)	2018-12-13	2021-09-17	萨勒普塔医疗公司	用于肌营养不良的外显子跳跃寡聚物缀合物
EP3898693A4 (en)	2018-12-21	2022-09-21	Avidity Biosciences, Inc.	ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
CN109837326B (zh) *	2019-01-17	2022-07-05	嘉兴学院	基于多价捕获并放大输出信号的生物靶标分子检测方法
EP3941924A4 (en) *	2019-03-20	2022-12-28	Wave Life Sciences Ltd.	USEFUL TECHNOLOGIES FOR THE PREPARATION OF OLIGONUCLEOTIDES
JP2022520885A (ja) *	2019-03-26	2022-04-01	ラトガース，ザステートユニバーシティオブニュージャージー	神経変性疾患を処置するための組成物および方法
EP3955966A1 (en)	2019-04-18	2022-02-23	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
WO2020236618A1 (en) *	2019-05-17	2020-11-26	Ionis Pharmaceuticals, Inc.	Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphate diester linkages
CN110346493B (zh) *	2019-05-23	2021-01-05	中国人民解放军军事科学院军事医学研究院	检测猕猴血浆中中期因子反义寡核苷酸含量的方法
US11578090B2 (en)	2019-06-06	2023-02-14	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
AU2020287880A1 (en)	2019-06-06	2022-01-20	Avidity Biosciences, Inc.	UNA amidites and uses thereof
WO2021188390A1 (en)	2020-03-19	2021-09-23	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
IL296393A (en)	2020-03-27	2022-11-01	Avidity Biosciences Inc	Preparations and methods for the treatment of muscle atrophy
CA3173647A1 (en)	2020-05-11	2021-11-18	Isabel AZNAREZ	Opa1 antisense oligomers for treatment of conditions and diseases
CN115885042A (zh)	2020-05-22	2023-03-31	波涛生命科学有限公司	双链寡核苷酸组合物及其相关方法
CN112063608B (zh) *	2020-08-27	2022-06-17	浙江工业大学	一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
CA3231330A1 (en)	2021-09-16	2023-03-23	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
KR20240070615A (ko)	2021-09-30	2024-05-21	사렙타 쎄러퓨틱스 인코퍼레이티드	하나 이상의 비염기성 유닛을 갖는 안티센스 올리고뉴클레오티드
CN114230498B (zh) *	2021-12-30	2023-11-17	湖北华世通生物医药科技有限公司	β-(二甲氨基)乙基对甲苯磺酸巯酯盐酸盐的制备方法
CN115181736B (zh) *	2022-01-07	2023-05-30	中国科学院海洋研究所	一种可以结合脂多糖的蛋白酶pck及其制备和应用
WO2023152371A1 (en)	2022-02-14	2023-08-17	Proqr Therapeutics Ii B.V.	Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013361A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Oligonucleotides for adar-mediated rna editing and use thereof
WO2024013360A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
WO2024064237A2 (en)	2022-09-21	2024-03-28	Sarepta Therapeutics, Inc.	Dmd antisense oligonucleotide-mediated exon skipping efficiency
GB202215614D0 (en)	2022-10-21	2022-12-07	Proqr Therapeutics Ii Bv	Heteroduplex rna editing oligonucleotide complexes
WO2024097310A2 (en) *	2022-11-01	2024-05-10	Impilo Therapeutics, Inc.	Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
WO2024110565A1 (en)	2022-11-24	2024-05-30	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en)	2022-12-01	2023-01-18	Proqr Therapeutics Ii Bv	Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en)	2022-12-09	2024-06-13	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en)	2023-01-20	2023-03-08	Proqr Therapeutics Ii Bv	Delivery of oligonucleotides

Family Cites Families (650)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2878264A (en)		1959-03-17		Substituted amino alcohols
DE133885C (pl)
US513030A (en)		1894-01-16		Machine for waxing or coating paper
CH372667A (de)	1957-09-26	1963-10-31	Robins Co Inc A H	Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
US3135766A (en)	1961-10-03	1964-06-02	Mead Johnson & Co	3-substituted-3-pyrrolidinols
US3484473A (en)	1967-05-12	1969-12-16	Buckman Labor Inc	Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de)	1968-07-10	1970-01-15	Pennwalt Corp	Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3745162A (en)	1970-08-31	1973-07-10	Robins Co Inc A H	1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en)	1973-02-24	1976-09-08	Beecham Group Ltd	Diphenylpropylamines
US4022791A (en)	1975-06-03	1977-05-10	Pfizer Inc.	2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en)	1975-08-09	1978-03-22	Beecham Group Ltd	Isoquinoline-derived aminoethers
BR7807288A (pt)	1977-11-08	1979-06-12	Genentech Inc	Processo para sintese de polinucleotidos
DD133885B1 (de)	1978-01-04	1981-02-25	Hans Lehmann	Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4542142A (en)	1982-11-22	1985-09-17	Roussel Uclaf	Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (de)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
USRE34069E (en)	1983-08-18	1992-09-15	Biosyntech Gmbh	Process for the preparation of oligonucleotides
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en)	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr)	1985-01-08	1987-04-03	Pasteur Institut	Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr)	1985-02-01	1988-01-08	Lafon Labor	Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
US4659774A (en)	1985-11-01	1987-04-21	American Hoechst Corporation	Support for solid-phase oligonucleotide synthesis
US4840956A (en)	1986-02-18	1989-06-20	Warner-Lambert Company	Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
US4735949A (en)	1986-02-18	1988-04-05	Warner-Lambert Company	Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
IL83663A0 (en)	1986-10-27	1988-01-31	Robins Co Inc A H	Preparation of 3-pyrrolidinols
CA1340032C (en)	1987-06-24	1998-09-08	Jim Haralambidis	Lucleoside derivatives
US5200553A (en)	1987-07-30	1993-04-06	Kupat Holim Health Insurance Institution Of The General Federation Of Labor	Biologically active carboxylic acid esters
US4923901A (en)	1987-09-04	1990-05-08	Millipore Corporation	Membranes with bound oligonucleotides and peptides
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5262530A (en)	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5047524A (en)	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja)	1989-08-17	1998-09-03	有機合成薬品工業株式会社	ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en)	1989-08-28	1992-08-25	Clontech Laboratories, Inc.	Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
WO1991009594A1 (en)	1989-12-28	1991-07-11	Virginia Commonwealth University	Sigma receptor ligands and the use thereof
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US5620963A (en)	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5914396A (en)	1990-01-11	1999-06-22	Isis Pharmaceuticals, Inc.	2'-O-modified nucleosides and phosphoramidites
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
EP1418179A3 (en)	1990-01-11	2006-03-08	Isis Pharmaceuticals, Inc.	Compositions and methods for detecting and modulating rna activity and gene expression
US5635488A (en)	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US5457191A (en)	1990-01-11	1995-10-10	Isis Pharmaceuticals, Inc.	3-deazapurines
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5292875A (en)	1990-04-20	1994-03-08	Lynx Therapeutics, Inc.	Method of synthesizing sulfurized oligonucleotide analogs
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
BR9106486A (pt)	1990-05-23	1993-05-25	Isis Pharmaceuticals Inc	Composicao para modulacao da atividade de um rna e processo para tratamento de um organismo que tem uma doenca que se caracteriza para producao indesejada de uma proteina
US5726017A (en)	1990-06-11	1998-03-10	Nexstar Pharmaceuticals, Inc.	High affinity HIV-1 gag nucleic acid ligands
US5543293A (en)	1990-06-11	1996-08-06	Nexstar Pharmaceuticals, Inc.	DNA ligands of thrombin
US5637459A (en)	1990-06-11	1997-06-10	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chimeric selex
US5869641A (en)	1990-06-11	1999-02-09	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands of CD4
US6001577A (en)	1998-06-08	1999-12-14	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5780228A (en)	1990-06-11	1998-07-14	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands to lectins
EP1493825A3 (en)	1990-06-11	2005-02-09	Gilead Sciences, Inc.	Method for producing nucleic acid ligands
US6261774B1 (en)	1990-06-11	2001-07-17	Gilead Sciences, Inc.	Truncation selex method
US6331394B1 (en)	1991-06-10	2001-12-18	Gilead Sciences, Inc.	Nucleic acid ligands to integrins
US5846713A (en)	1990-06-11	1998-12-08	Nexstar Pharmaceuticals, Inc.	High affinity HKGF nucleic acid ligands and inhibitors
US5705337A (en)	1990-06-11	1998-01-06	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6232071B1 (en)	1990-06-11	2001-05-15	Gilead Sciences, Inc.	Tenascin-C nucleic acid ligands
US5527894A (en)	1990-06-11	1996-06-18	Nexstar Pharmacueticals, Inc.	Ligands of HIV-1 tat protein
US5503978A (en)	1990-06-11	1996-04-02	University Research Corporation	Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5496938A (en)	1990-06-11	1996-03-05	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to HIV-RT and HIV-1 rev
US5587468A (en)	1990-06-11	1996-12-24	University Research Corporation	High affinity nucleic acid ligands to HIV integrase
US5654151A (en)	1990-06-11	1997-08-05	Nexstar Pharmaceuticals, Inc.	High affinity HIV Nucleocapsid nucleic acid ligands
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5683867A (en)	1990-06-11	1997-11-04	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: blended SELEX
US5861254A (en)	1997-01-31	1999-01-19	Nexstar Pharmaceuticals, Inc.	Flow cell SELEX
US5668264A (en)	1990-06-11	1997-09-16	Nexstar Pharmaceuticals, Inc.	High affinity PDGF nucleic acid ligands
US5580737A (en)	1990-06-11	1996-12-03	Nexstar Pharmaceuticals, Inc.	High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
CA2088258C (en)	1990-07-27	2004-09-14	Phillip Dan Cook	Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5610289A (en) *	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en)	1991-03-06	1996-04-30	Polish Academy Of Sciences	Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US6414112B1 (en)	1991-05-24	2002-07-02	Ole Buchardt	Peptide nucleic acids having 2,6-diaminopurine nucleobases
JPH04348077A (ja)	1991-05-24	1992-12-03	Nec Corp	薄膜トランジスタ
AU659649B2 (en)	1991-06-10	1995-05-25	Lucky Limited	Hepatitis C diagnostics and vaccines
US5646267A (en)	1991-08-05	1997-07-08	Polish Academy Of Sciences	Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en)	1991-08-05	1994-10-25	Polish Academy Of Sciences	Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5654284A (en)	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en)	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5599797A (en)	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5607923A (en)	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
CA2121144C (en)	1991-10-15	2001-07-31	Phillip Dan Cook	Oligonucleotides having chiral phosphorus linkages
US5576302A (en)	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
ATE515510T1 (de)	1991-12-24	2011-07-15	Isis Pharmaceuticals Inc	Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
JPH08500481A (ja)	1992-05-11	1996-01-23	リボザイム・ファーマシューティカルズ・インコーポレーテッド	ウイルスの複製を阻害するための方法および薬剤
GB9213601D0 (en)	1992-06-26	1992-08-12	Mastico Robert A	Protein based delivery system
JPH07509133A (ja)	1992-07-17	1995-10-12	リボザイム・ファーマシューティカルズ・インコーポレイテッド	動物疾患の処置のための方法および剤
US7067497B2 (en)	1992-09-29	2006-06-27	Isis Pharmaceuticals, Inc.	Modulation of telomere length by oligonucleotides having a G-core sequence
DE69400208T2 (de)	1993-01-25	1996-11-28	Hybridon Inc	Olionukleotidalkylphosphonate und -phosphonothioate
HU9501994D0 (en)	1993-03-31	1995-09-28	Sterling Winthrop Inc	Novel 5'-substituted nucleosides and oligomers produced therefrom
US5955591A (en)	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
DE69412704T2 (de)	1993-06-10	1999-02-04	Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo	Spritzgiessform
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5643989A (en)	1993-10-29	1997-07-01	Azdel, Inc.	Fiber reinforced functionalized polyolefin composites
DK0732929T3 (da)	1993-10-29	2008-09-01	Brigham & Womens Hospital	Terapeutisk anvendelse af cis-element-afledere in vivo
WO1998003542A1 (en)	1996-07-24	1998-01-29	Buchardt, Dorte	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de)	1994-01-19	1995-07-20	Boehringer Mannheim Gmbh	Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
WO1995021853A1 (en)	1994-02-10	1995-08-17	Nexstar Pharmaceuticals, Inc.	High-affinity ligands of basic fibroblast growth factor and thrombin
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
JP3553958B2 (ja)	1994-02-22	2004-08-11	ノボザイムスアクティーゼルスカブ	脂質分解酵素の変異体の製造方法
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995031533A1 (en)	1994-05-11	1995-11-23	Novo Nordisk A/S	AN ENZYME WITH ENDO-1,3(4)-β-GLUCANASE ACTIVITY
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
EP0772619B2 (en)	1994-07-15	2010-12-08	The University of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
JPH10505094A (ja)	1994-09-07	1998-05-19	ハイブリドン・インコーポレイテッド	オリゴヌクレオチドプロドラッグ
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
CN1175281A (zh)	1994-12-22	1998-03-04	海布里登公司	立体特异性硫代磷酸寡核苷酸的合成
GB9501465D0 (en)	1995-01-25	1995-03-15	King S College London	Nucleoside phosphorothioate derivatives,synthesis and use thereof
WO1996027604A1 (en)	1995-03-06	1996-09-12	Nexstar Pharmaceuticals, Inc.	High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
AU5359496A (en)	1995-03-06	1996-09-23	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0739983B1 (en)	1995-04-27	2009-12-30	Takara Bio Inc.	Gene encoding lacto-n-biosidase
CA2220433C (en)	1995-05-11	2010-02-16	Applied Research Systems Ars Holding N.V.	Il-6 activity inhibitor
AU5871196A (en)	1995-05-23	1996-12-24	Hybridon, Inc.	Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
ES2151173T3 (es)	1995-05-23	2000-12-16	Hybridon Inc	Nuevos sintones para la sintesis estereoselectiva de oligonucleotidos.
CA2223103A1 (en)	1995-06-06	1996-12-12	Isis Pharmaceuticals Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US6111095A (en)	1995-06-07	2000-08-29	Merck & Co., Inc.	Capped synthetic RNA, analogs, and aptamers
US6699843B2 (en)	1995-06-07	2004-03-02	Gilead Sciences, Inc.	Method for treatment of tumors using nucleic acid ligands to PDGF
US5932450A (en)	1995-06-07	1999-08-03	Gen-Probe Incorporated	Enzymatic synthesis of oligonucleotides using digestible templates
EP0759470B1 (en)	1995-06-29	2006-10-25	Takara Bio Inc.	Gene encoding endoglycoceramidase activator
US5795765A (en)	1995-06-29	1998-08-18	Takara Shuzo Co., Ltd.	Gene encoding endoglycoceramidase
US6017700A (en) *	1995-08-04	2000-01-25	Bayer Corporation	Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en)	1996-05-24	1999-08-10	Genta Incorporated	Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en)	1995-09-05	1997-03-13	Michigan State University	PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5734041A (en)	1995-10-20	1998-03-31	Mcgill University	Preparation of chiral phosphorothioate oligomers
US6476216B1 (en)	1995-10-20	2002-11-05	Mcgill University	Preparation of phosphorothioate oligomers
US5856085A (en)	1995-12-01	1999-01-05	The Penn State Research Foundation	Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
ATE468396T1 (de)	1996-02-01	2010-06-15	Gilead Sciences Inc	Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
CA2246503A1 (en)	1996-02-15	1997-08-21	National Institutes Of Health	Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US6214805B1 (en)	1996-02-15	2001-04-10	The United States Of America As Represented By The Department Of Health And Human Services	RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en)	1996-03-05	1996-05-01	Ciba Geigy Ag	Chemical compounds
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997043409A2 (en)	1996-05-10	1997-11-20	Novo Nordisk A/S	Method of providing novel dna sequences
US5856465A (en)	1996-05-24	1999-01-05	Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych	Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
DE19622783A1 (de)	1996-06-07	1997-12-11	Hoechst Ag	Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
EP0912767B1 (en)	1996-07-16	2006-09-13	Gen-Probe Incorporated	Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm
AU4156197A (en)	1996-08-21	1998-03-06	Hybridon, Inc.	Oligonucleotide prodrugs
WO1998008809A1 (en)	1996-08-30	1998-03-05	Hybridon, Inc.	Novel sulfur transfer reagents for oligonucleotide synthesis
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
US6051698A (en)	1997-06-06	2000-04-18	Janjic; Nebojsa	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AU5720098A (en)	1996-12-27	1998-07-31	Icn Pharmaceuticals, Inc.	G-rich oligo aptamers and methods of modulating an immune response
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en)	1997-03-07	2002-04-09	President And Fellows Of Harvard College	DNA glycosylase inhibitors, and uses related thereto
US6015887A (en)	1997-04-11	2000-01-18	Isis Pharmaceuticals, Inc.	Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en)	1997-04-21	2002-10-22	The Cleveland Clinic Foundation	RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl)	1997-04-25	2002-11-29	Pan	Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
CA2291839A1 (en)	1997-05-28	1998-12-03	Peter E. Nielsen	Conjugated peptide nucleic acids having enhanced cellular uptake
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999005160A2 (en)	1997-07-25	1999-02-04	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en)	2001-07-30	2004-07-27	Isis Pharmaceuticals Inc.	Antisense modulation of microsomal triglyceride transfer protein expression
US6383808B1 (en)	2000-09-11	2002-05-07	Isis Pharmaceuticals, Inc.	Antisense inhibition of clusterin expression
GB9717158D0 (en)	1997-08-13	1997-10-22	King S College London	Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6750344B1 (en)	1997-09-05	2004-06-15	Isis Pharmaceuticals, Inc.	Amine compounds and combinatorial libraries comprising same
DE19741715A1 (de)	1997-09-22	1999-03-25	Hoechst Ag	Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6080543A (en)	1997-12-08	2000-06-27	E. & J. Gallo Winery	Detection of fungal pathogens
US6582936B1 (en)	1997-12-12	2003-06-24	The Regents Of The University Of California	Methods for making nucleic acids
US6248519B1 (en)	1998-03-11	2001-06-19	E & J Gallo Winery	Detection of fermentation-related microorganisms
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
EP1077708A1 (en)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO1999058118A2 (en)	1998-05-14	1999-11-18	Cpg Immunopharmaceuticals Gmbh	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
US6867294B1 (en) *	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
AU764532B2 (en)	1998-07-27	2003-08-21	University Of Iowa Research Foundation, The	Stereoisomers of CpG oligonucleotides and related methods
JP4620251B2 (ja)	1998-08-10	2011-01-26	アンチジェニックス・インコーポレイテッド	Ｃｐｇおよびサポニンアジュバントの組成物並びにその方法
DE69929699T2 (de)	1998-08-14	2006-08-24	Japan Science And Technology Agency, Kawaguchi	Nukleinsäure, die spezifisch an ein ras zielprotein binden kann
WO2000023444A1 (en)	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en)	1998-10-23	2006-02-07	Sirna Therapeutics, Inc.	Method for the chemical synthesis of oligonucleotides
US6867289B1 (en)	1998-10-26	2005-03-15	Board Of Regents, The University Of Texas Systems	Thio-modified aptamer synthetic methods and compositions
US6451524B1 (en)	1998-11-25	2002-09-17	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
AU1742600A (en)	1998-11-25	2000-06-13	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
JP2002533087A (ja)	1998-12-21	2002-10-08	ジェネンカーインターナショナル，インコーポレイティド	複数荷電変種を有する化学修飾酵素
AU1853600A (en)	1999-01-06	2000-07-24	Choong-Chin Liew	Method for the detection of gene transcripts in blood and uses thereof
US6265172B1 (en)	1999-02-08	2001-07-24	University Of Kentucky	Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en)	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US6506594B1 (en)	1999-03-19	2003-01-14	Cornell Res Foundation Inc	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en)	1999-03-29	1999-05-26	Goldsborough Andrew	Cleavage of nucleic acids from solid supports
JP3072345B1 (ja)	1999-03-31	2000-07-31	農林水産省家畜衛生試験場長	豚丹毒菌の組換えサブユニットワクチン
DE19916417A1 (de)	1999-04-01	2000-10-19	Schering Ag	Amyloidspezifisches Aptamer
AU775412B2 (en)	1999-04-08	2004-07-29	Advanced Cancer Therapeutics, Inc.	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en)	1999-05-03	2001-10-09	Qiagen Gmbh	Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6066500A (en)	1999-06-25	2000-05-23	Isis Pharmaceuticals Inc.	Antisense modulation of Beta catenin expression
US6271004B1 (en)	1999-06-25	2001-08-07	Display Systems Biotech A/S	Method for improved reverse transcription at high temperatures
US6569630B1 (en)	1999-07-02	2003-05-27	Conceptual Mindworks, Inc.	Methods and compositions for aptamers against anthrax
US6414135B1 (en)	1999-07-07	2002-07-02	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en)	2001-08-08	2003-05-15	Crooke Rosanne M.	Antisense modulation of cholesteryl ester transfer protein expression
DE19935756A1 (de)	1999-07-27	2001-02-08	Mologen Forschungs Entwicklung	Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US6171795B1 (en)	1999-07-29	2001-01-09	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to CD40ligand
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US7264932B2 (en)	1999-09-24	2007-09-04	Applera Corporation	Nuclease inhibitor cocktail
JP2003510282A (ja)	1999-09-25	2003-03-18	ユニバーシティオブアイオワリサーチファウンデーション	免疫刺激核酸
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en)	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en)	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
IL148922A0 (en)	1999-10-06	2002-09-12	Quark Biotech Inc	Method for enrichment of natural antisense messenger rna
JP3463098B2 (ja)	1999-10-08	2003-11-05	独立行政法人産業技術総合研究所	モジュレートアプタマー及びこれを用いた標的タンパク質の検出方法
GB9924285D0 (en)	1999-10-14	1999-12-15	Avecia Ltd	Process
US20010055761A1 (en)	1999-10-29	2001-12-27	Agilent Technologies	Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr)	1999-11-05	2003-01-31	Centre Nat Rech Scient	Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
WO2001040515A1 (en)	1999-11-12	2001-06-07	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en)	1999-12-27	2001-11-27	Technion Research And Development Foundation Ltd.	Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
WO2001050349A1 (en)	1999-12-30	2001-07-12	Rutgers, The State University Of New Jersey	Electronic document customization and transformation utilizing user feedback
JP2004510953A (ja)	1999-12-30	2004-04-08	キャボット　コーポレイション	改良された性質を有するセンサー
US6649750B1 (en)	2000-01-05	2003-11-18	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotide compounds
US6159697A (en)	2000-01-19	2000-12-12	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad7 expression
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2335389A1 (en)	2000-03-01	2001-09-01	Message Pharmaceuticals, Inc.	Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
GB0004889D0 (en)	2000-03-01	2000-04-19	Avecia Ltd	Synthesis of oligonucleotides
WO2001070663A2 (en)	2000-03-17	2001-09-27	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
DE10019756A1 (de)	2000-04-20	2001-10-25	Bayer Ag	Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
CN1178911C (zh)	2000-04-20	2004-12-08	弗·哈夫曼-拉罗切有限公司	吡咯烷与哌啶衍生物和它们用于治疗神经变性疾病的用途
AU2001259706A1 (en)	2000-05-09	2001-11-20	Reliable Biopharmaceutical, Inc.	Polymeric compounds useful as prodrugs
US6492171B2 (en)	2000-05-16	2002-12-10	Isis Pharmaceuticals, Inc.	Antisense modulation of TERT expression
US6725412B1 (en)	2000-08-15	2004-04-20	Dolby Laboratories Licensing Corporation	Low latency data encoder
US6809195B1 (en)	2000-08-16	2004-10-26	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotides
US6559279B1 (en)	2000-09-08	2003-05-06	Isis Pharmaceuticals, Inc.	Process for preparing peptide derivatized oligomeric compounds
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
US6376190B1 (en)	2000-09-22	2002-04-23	Somalogic, Inc.	Modified SELEX processes without purified protein
EP2351855A1 (en)	2000-09-26	2011-08-03	Duke University	RNA aptamers and methods for identifying the same
GB0024752D0 (en)	2000-10-10	2000-11-22	Univ Belfast	Oxidative halogenation of aromatic compounds
JP4176466B2 (ja)	2000-10-16	2008-11-05	ギリード・サイエンシズ・インコーポレーテッド	前立腺特異的膜抗原に対する核酸リガンド
MXPA03003408A (es)	2000-10-18	2005-06-30	Glaxosmithkline Biolog Sa	Vacunas.
US6682889B1 (en)	2000-11-08	2004-01-27	Becton, Dickinson And Company	Amplification and detection of organisms of the Chlamydiaceae family
JP2002165594A (ja)	2000-11-29	2002-06-11	National Institute Of Advanced Industrial & Technology	Ｃ型肝炎ウイルスのｉｒｅｓ及びｎｓ３プロテアーゼを標的とするｒｎａ分子
NL1016978C2 (nl)	2000-12-22	2002-06-25	Robert Jan Colenbrander	Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
KR100828453B1 (ko)	2001-01-22	2008-05-13	머크 앤드 캄파니 인코포레이티드	Ｒｎａ 의존성 ｒｎａ 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
US8008459B2 (en)	2001-01-25	2011-08-30	Evolva Sa	Concatemers of differentially expressed multiple genes
WO2002059297A2 (en)	2001-01-25	2002-08-01	Evolva Biotech A/S	A library of a collection of cells
AU2002224668B2 (en)	2001-01-26	2007-09-20	Commonwealth Scientific And Industrial Research Organisation	Methods and means for producing efficient silencing construct using recombinational cloning
EP1383782A1 (en)	2001-03-26	2004-01-28	Sirna Therpeutics, Inc.	Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20050277133A1 (en)	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030207804A1 (en)	2001-05-25	2003-11-06	Muthiah Manoharan	Modified peptide nucleic acids
GB0113523D0 (en)	2001-06-04	2001-07-25	Torotrak Dev Ltd	An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en)	2001-06-14	2003-04-10	Isis Pharmaceuticals, Inc.	Methods for preparing oligonucleotides having chiral phosphorothioate linkages
CN1636015A (zh)	2001-06-29	2005-07-06	希龙公司	Hcv e1e2疫苗组合物
CA2452458A1 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
US7205399B1 (en)	2001-07-06	2007-04-17	Sirna Therapeutics, Inc.	Methods and reagents for oligonucleotide synthesis
US6440739B1 (en)	2001-07-17	2002-08-27	Isis Pharmaceuticals, Inc.	Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US6455308B1 (en)	2001-08-01	2002-09-24	Isis Pharmaceuticals, Inc.	Antisense modulation of serum amyloid A4 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7259150B2 (en)	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7354909B2 (en)	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
WO2003017930A2 (en)	2001-08-24	2003-03-06	Massachusetts Institute Of Technology	Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en)	2001-09-21	2006-05-23	Academia Sinica	Mutant-type lipases and applications thereof
US6933288B2 (en)	2002-02-04	2005-08-23	Isis Pharmaceuticals, Inc.	Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja)	2002-02-12	2009-10-21	株式会社キラルジェン	立体規則性の高いジヌクレオシドホスホロチオエートの製造法
WO2003106476A1 (en)	2002-02-20	2003-12-24	Sirna Therapeutics, Inc	Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US20050096284A1 (en)	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US8232383B2 (en)	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7288376B2 (en)	2002-03-22	2007-10-30	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en)	2002-11-23	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of huntingtin interacting protein 2 expression
AU2003237875A1 (en)	2002-05-15	2003-12-02	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein b expression
AU2003241621A1 (en)	2002-05-24	2003-12-12	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
WO2003099840A1 (en)	2002-05-24	2003-12-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
AU2003238772A1 (en)	2002-05-31	2003-12-19	Regents Of The University Of Minnesota	In vitro evaluation of nucleic acid ligands
US7507808B2 (en)	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
WO2003106477A1 (en)	2002-06-01	2003-12-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
JP4598519B2 (ja)	2002-06-20	2010-12-15	サイトスバイオテクノロジーアーゲー	アジュバントとして使用するためのパッケージ化されたウィルス様粒子：調製法及び使用法
WO2004003228A1 (en)	2002-07-01	2004-01-08	Unisearch Limited	Genotyping method
ES2550609T3 (es)	2002-07-10	2015-11-11	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Interferencia de ARN mediante de moléculas de ARN de cadena sencilla
US20040023905A1 (en)	2002-07-31	2004-02-05	Isis Pharmaceuticals Inc.	Antisense modulation of LAR expression
EP1386972A1 (en)	2002-08-01	2004-02-04	Noxxon Pharma AG	Method and apparatus for designing a nucleic acid having a desired property
US20050255086A1 (en)	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en)	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
WO2004014933A1 (en)	2002-08-07	2004-02-19	University Of Massachusetts	Compositions for rna interference and methods of use thereof
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US7414116B2 (en)	2002-08-23	2008-08-19	Illumina Cambridge Limited	Labelled nucleotides
CA2498777C (en)	2002-09-13	2015-01-13	Replicor, Inc.	Non-sequence complementary antiviral oligonucleotides
US7030230B2 (en)	2002-10-25	2006-04-18	Isis Pharmaceuticals, Inc.	Process of purifying phosphoramidites
DK2241325T3 (da)	2002-10-29	2012-04-10	Coley Pharm Group Inc	Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
US7696345B2 (en)	2002-11-05	2010-04-13	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044141A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Conjugated oligomeric compounds and their use in gene modulation
AU2003291721A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US7381527B2 (en)	2002-11-06	2008-06-03	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
JP4986109B2 (ja)	2002-11-13	2012-07-25	ジェンザイム・コーポレーション	アポリポタンパク質ｂ発現のアンチセンス調節
EP2305813A3 (en)	2002-11-14	2012-03-28	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
WO2004080406A2 (en)	2003-03-07	2004-09-23	Alnylam Pharmaceuticals	Therapeutic compositions
GB0305422D0 (en)	2003-03-10	2003-04-16	Univ Open	Detection, monitoring and treatment of cancer
CA2524255C (en)	2003-03-21	2014-02-11	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en)	2003-03-24	2003-04-30	Avecia Ltd	Process and compounds
EP1605973B1 (en)	2003-03-26	2012-09-26	Cytos Biotechnology AG	Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
CA2523260A1 (en)	2003-04-21	2004-11-04	Archemix Corporation	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7045306B2 (en)	2003-04-28	2006-05-16	The General Hospital Corporation	Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en)	2003-05-07	2007-05-08	E. I. Du Pont De Nemours And Company	Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
CA2526893C (en)	2003-05-14	2010-10-26	Japan Science And Technology Agency	Inhibition of the expression of huntingtin gene
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7410975B2 (en)	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2011088935A (ja)	2003-08-08	2011-05-06	Chiralgen Ltd	リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
JP2005089441A (ja)	2003-08-08	2005-04-07	Toudai Tlo Ltd	立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
ES2382807T3 (es)	2003-08-28	2012-06-13	Takeshi Imanishi	Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
WO2005023828A1 (ja)	2003-09-02	2005-03-17	Takeshi Wada	リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
JP4616175B2 (ja)	2003-09-02	2011-01-19	株式会社キラルジェン	５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
DK1667522T3 (en)	2003-09-09	2018-03-05	Geron Corp	MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en)	2003-09-09	2005-04-07	Monia Brett P.	Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US8680063B2 (en)	2003-09-12	2014-03-25	University Of Massachusetts	RNA interference for the treatment of gain-of-function disorders
EP1670518B1 (en)	2003-09-12	2014-05-21	University of Massachusetts	Rna interference for the treatment of gain-of-function disorders
GB0323968D0 (en)	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
WO2005042716A2 (en)	2003-10-31	2005-05-12	President And Fellows Of Harvard College	Nucleic acid binding oligonucleotides
US7846436B2 (en)	2003-11-28	2010-12-07	Chemgenes Corporation	Oligonucleotides and related compounds
JP4945129B2 (ja)	2004-01-27	2012-06-06	株式会社キラルジェン	フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en)	2004-02-06	2005-08-11	Dharmacon, Inc.	SNP discriminatory siRNA
US20080221303A1 (en)	2004-02-18	2008-09-11	Jehoshua Katzhendler	Method for the Preparation of Peptide-Oligonucleotide Conjugates
JP3976742B2 (ja)	2004-02-27	2007-09-19	江守商事株式会社	インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US20060193821A1 (en)	2004-03-05	2006-08-31	Diener John L	Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2005085272A1 (ja)	2004-03-05	2005-09-15	Takeshi Wada	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005092909A1 (ja)	2004-03-25	2005-10-06	Toudai Tlo, Ltd.	立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
US20050267300A1 (en)	2004-04-05	2005-12-01	Muthiah Manoharan	Processes and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
JP2007534339A (ja)	2004-04-26	2007-11-29	アーケミックスコーポレイション	免疫グロブリンｅに特異的な核酸リガンドおよびアトピー性疾患治療としてのその使用
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
CA2572795A1 (en)	2004-05-27	2005-12-08	The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services	Differential expression of molecules associated with acute stroke
US7759318B1 (en)	2004-05-28	2010-07-20	Isis Pharmaceuticals, Inc.	Identification of novel pathways, genes and promoter motifs regulating adipogenesis
CA2568735A1 (en)	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
PT1766010E (pt)	2004-06-28	2011-05-25	Univ Western Australia	Oligonucle?tidos antisense para a indu??o de skipping de ex?es e seus m?todos de utiliza??o
DK2997980T3 (en)	2004-08-10	2018-03-26	Kastle Therapeutics Llc	PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS
KR101281836B1 (ko)	2004-08-26	2013-07-03	니뽄 신야쿠 가부시키가이샤	포스포라미다이트 화합물 및 올리고 ｒｎａ의 제조 방법
CA2579374A1 (en)	2004-09-07	2006-03-30	Archemix Corp.	Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
CA2578046A1 (en)	2004-09-07	2006-03-16	Archemix Corp.	Aptamer medicinal chemistry
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006031461A2 (en)	2004-09-09	2006-03-23	Isis Pharmaceuticals, Inc.	Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
CA2580504C (en)	2004-09-17	2013-10-29	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
AU2005295756B2 (en)	2004-10-13	2012-02-02	Isis Parmaceuticals, Inc.	Antisense modulation of PTP1B expression
KR100721928B1 (ko)	2004-11-05	2007-05-28	주식회사 바이오씨에스	ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (en)	2004-11-16	2006-05-17	Immunotech S.A.	Oligonucleotides that induce the secretion of GM-CSF
EP1819365B1 (en)	2004-12-09	2014-07-02	Alnylam Pharmaceuticals Inc.	Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
WO2006065751A2 (en)	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en)	2004-12-17	2006-06-22	Thiosense, Inc.	Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20060183763A1 (en)	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
US20060166901A1 (en)	2005-01-03	2006-07-27	Yu Ruey J	Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
CA2549423C (en)	2005-01-28	2012-10-02	Hyung-Joo Kwon	Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
EP1851314A2 (en)	2005-02-24	2007-11-07	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
JP2006248949A (ja) *	2005-03-09	2006-09-21	Univ Nagoya	ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
CN101189249B (zh)	2005-04-01	2013-04-17	加利福尼亚大学董事会	膦酰基-戊-2-烯-1-基核苷和类似物
RU2427377C2 (ru)	2005-05-05	2011-08-27	Антисенс Фарма Гмбх	Дозирование олигонуклеотидов
US7902352B2 (en)	2005-05-06	2011-03-08	Medtronic, Inc.	Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en)	2005-05-06	2006-11-16	Medtronic, Inc.	Methods and sequences to suppress primate huntington gene expression
WO2006138676A2 (en)	2005-06-15	2006-12-28	The Ohio State University Research Foundation	Aptamers that bind to prion protein
US10242753B2 (en)	2005-06-17	2019-03-26	University Of Washington	Method for measuring strength of associations of multidimensional traits
EP2548560B1 (en)	2005-06-23	2015-06-03	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of SMN2 splicing
EP2062980B1 (en)	2005-06-28	2011-08-31	Medtronic, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
US9133517B2 (en)	2005-06-28	2015-09-15	Medtronics, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1948600B1 (en)	2005-07-05	2014-04-16	The President & Fellows Of Harvard College	Liver targeted conjugates
JP4984634B2 (ja)	2005-07-21	2012-07-25	ソニー株式会社	物理情報取得方法および物理情報取得装置
CA2641599C (en)	2005-07-28	2012-07-10	Id-Fish Technology, Inc.	Method for improving cell permeability to foreign particles
EP1928505A4 (en)	2005-08-26	2010-10-27	Archemix Corp	APTAMERS BINDING TO THROMBIN WITH STRONG AFFINITY
CA2620856C (en)	2005-08-29	2017-11-28	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
WO2007028065A2 (en) *	2005-08-30	2007-03-08	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds for modulation of splicing
US8367627B2 (en)	2005-09-15	2013-02-05	Duke University	Focused libraries, functional profiling, laser SELEX, and DESELEX
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en)	2005-09-30	2007-04-05	Midgley Timothy M	Method and apparatus for collecting user game play data and crediting users in a gaming environment
AU2006304205C1 (en)	2005-10-12	2012-11-15	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
WO2007049416A1 (ja)	2005-10-28	2007-05-03	Tosoh Corporation	カロテノイド合成微生物の作製方法およびカロテノイドの製造方法
WO2007051045A2 (en)	2005-10-28	2007-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
JP2009515896A (ja)	2005-11-11	2009-04-16	ファイザー・インク	免疫調節性オリゴデオキシヌクレオチドを使用する併用療法
WO2007064291A1 (en)	2005-11-30	2007-06-07	Jyoti Chattopadhyaya	Method and compounds for rna synthesis
CA2632968A1 (en)	2005-12-02	2007-06-07	Isis Pharmaceuticals, Inc.	Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
PL1979356T3 (pl)	2005-12-21	2014-01-31	Pfizer Prod Inc	Karbonyloaminopirolopirazole, inhibitory kinazy białkowej
EP1991677A2 (en)	2006-01-26	2008-11-19	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to huntingtin
CN102908630B (zh)	2006-01-27	2014-11-19	Isis制药公司	6-修饰的双环核酸类似物
EP2135949B1 (en)	2006-02-14	2012-10-17	Noxxon Pharma AG	MCP-1 binding nucleic acids
PT2405002E (pt)	2006-02-15	2015-01-05	Adiutide Pharmaceuticals Gmbh	Composições e métodos para formulações de oligonucleotídeos
BRPI0708588A2 (pt)	2006-03-08	2011-06-07	Archemix Corp	aptámeros de ligaçao ao complemento e agentes anti-c5 usados no tratamento de desordens oculares
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
CN101454315B (zh)	2006-03-31	2016-08-17	应用生物***有限责任公司	用于合成罗丹明-标记的寡核苷酸的试剂
WO2007118222A2 (en)	2006-04-06	2007-10-18	Ibis Biosciences, INC	Compositions for the use in identification of fungi
ES2348122T3 (es)	2006-04-20	2010-11-30	F. Hoffmann-La Roche Ag	Derivados de diazepano moduladores de receptores de quimioquina.
CN101432440B (zh)	2006-04-24	2013-08-21	西格马食品可变资本有限公司	通过实时聚合酶链反应检测和多重、同时量化病原体的方法
WO2007127221A2 (en)	2006-04-25	2007-11-08	Immune Disease Institute Inc.	Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
WO2007131232A2 (en)	2006-05-05	2007-11-15	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to ptpr alpha
EP2023940B1 (en)	2006-05-05	2011-06-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of sglt2
US20090012120A1 (en)	2006-05-10	2009-01-08	Board Of Trustees Of Michigan State University	Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
US7547684B2 (en)	2006-05-11	2009-06-16	Isis Pharmaceuticals, Inc.	5′-modified bicyclic nucleic acid analogs
EP2026653A4 (en)	2006-05-26	2011-11-16	Regado Biosciences Inc	ADMINISTRATION OF REG1 ANTICOAGULATION SYSTEM
JP5161770B2 (ja)	2006-05-31	2013-03-13	東レ株式会社	免疫刺激オリゴヌクレオチド及びその医薬用途
US8097596B2 (en)	2006-06-30	2012-01-17	Lakewood-Amedex, Inc.	Compositions and methods for the treatment of muscle wasting
CA2662704A1 (en)	2006-07-07	2008-01-10	University Of Massachusetts	Rna silencing compositions and methods for the treatment of huntington's disease
US9233106B2 (en)	2006-07-12	2016-01-12	Cornell Research Foundation, Inc.	Inhibition of beta-amyloid peptide aggregation
EP2046964B1 (en)	2006-07-12	2018-07-04	The Regents of The University of California	Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
PL2041282T3 (pl)	2006-07-18	2018-07-31	Noxxon Pharma Ag	Kwasy nukleinowe wiążące sdf-i
EP2051977A2 (en)	2006-07-20	2009-04-29	Amgen Inc.	SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
CN100503824C (zh)	2006-07-20	2009-06-24	武汉大学	抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
WO2008017081A1 (en)	2006-08-04	2008-02-07	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of jnk proteins
AT504194B1 (de)	2006-09-07	2008-07-15	Oesterr Rotes Kreuz	Bakteriennachweis
EP1897562A1 (en)	2006-09-08	2008-03-12	Bayer Schering Pharma Aktiengesellschaft	Aptamers labelled with Gallium-68
US8138330B2 (en)	2006-09-11	2012-03-20	Sigma-Aldrich Co. Llc	Process for the synthesis of oligonucleotides
KR101251707B1 (ko)	2006-09-27	2013-04-11	콜리 파마슈티칼 게엠베하	면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
DK2410054T4 (da)	2006-10-18	2020-02-10	Ionis Pharmaceuticals Inc	Antisenseforbindelser
AU2007309195A1 (en)	2006-10-23	2008-05-02	Irm Llc	Cathepsin proteases inhibitors
WO2008139262A2 (en)	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
FR2908414B1 (fr)	2006-11-13	2012-01-20	Centre Nat Rech Scient	Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
US8754107B2 (en)	2006-11-17	2014-06-17	Abbvie Inc.	Aminopyrrolidines as chemokine receptor antagonists
WO2008066776A2 (en)	2006-11-27	2008-06-05	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
KR100861108B1 (ko)	2006-11-28	2008-09-30	(주) 벡스코아	씨형 간염 바이러스 레플리콘 증식을 억제하는 알엔에이분해효소 저항성 알엔에이 압타머
CN101610671A (zh)	2006-12-12	2009-12-23	艾德拉药物股份有限公司	合成的tlr9激动剂
UY30892A1 (es)	2007-02-07	2008-09-02	Smithkline Beckman Corp	Inhibidores de la actividad akt
US20100190837A1 (en)	2007-02-15	2010-07-29	Isis Pharmaceuticals, Inc.	5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
BRPI0809320A2 (pt)	2007-03-24	2014-09-23	Genzyme Corp	Método
AU2008247427A1 (en) *	2007-05-03	2008-11-13	Rosetta Inpharmatics Llc	Compositions comprising miR34 therapeutic agents for treating cancer
HUE025701T2 (en)	2007-05-11	2016-04-28	Adynxx Inc	Gene expression and pain
EP2149571A4 (en)	2007-05-24	2010-09-01	Kyorin Seiyaku Kk	MUTILINE DERIVATIVE WITH A RINGED, HETEROCYCLIC AND AROMATIC CARBOXYLIC ACID STRUCTURE IN A SUBSTITUTE AT POSITION 14
GB0710186D0 (en)	2007-05-29	2007-07-04	Texas Instr Denmark	PWM loop with minimum allasing error property
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
BRPI0812740A2 (pt)	2007-06-05	2016-07-19	Nsab Af Neurosearch Sweden Ab	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
WO2008151833A2 (en)	2007-06-13	2008-12-18	Hochschule Mannheim	Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
EP2014769B1 (en)	2007-06-18	2010-03-31	Commissariat à l'Energie Atomique	Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
US8278283B2 (en)	2007-07-05	2012-10-02	Isis Pharmaceuticals, Inc.	6-disubstituted or unsaturated bicyclic nucleic acid analogs
CA2692161C (en)	2007-07-09	2015-09-29	Idera Pharmaceuticals, Inc.	Stabilized immune modulatory rna (simra) compounds
US8008011B2 (en)	2007-07-31	2011-08-30	University Of Saskatchewan	Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
EP2185700A4 (en)	2007-08-02	2010-11-24	Texas A & M Univ Sys	ANTISENSE MICRO RNA AND USES THEREOF
US8853375B2 (en)	2007-08-15	2014-10-07	Idera Pharmaceuticals, Inc.	Toll like receptor modulators
US8486904B2 (en)	2007-10-01	2013-07-16	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
KR100886139B1 (ko)	2007-11-13	2009-02-27	주식회사 삼천리제약	올리고뉴클레오타이드의 제조방법
TW200930375A (en)	2007-12-21	2009-07-16	Exelixis Inc	Benzofuropyrimidinones
TWI340765B (en)	2007-12-26	2011-04-21	Ind Tech Res Inst	Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089689A1 (en)	2008-01-15	2009-07-23	Mediatek Inc.	Multimedia presenting system, multimedia processing apparatus thereof, and method for presenting video and audio signals
WO2009089659A1 (en)	2008-01-18	2009-07-23	Shanghai Targetdrug Co., Ltd.	Pyrollidine-based compounds
CA2711587A1 (en)	2008-02-04	2009-08-13	Galapagos Nv	Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (ja)	2008-02-12	2009-08-27	Tokyo Institute Of Technology	オリゴヌクレオチド誘導体
EP2282744B1 (en)	2008-03-21	2018-01-17	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
US20110269814A1 (en)	2008-03-26	2011-11-03	Alnylam Pharamaceuticals, Inc.	2'-f modified rna interference agents
CN103816174B (zh)	2008-04-03	2017-12-05	春堤制药公司	用于治疗病毒感染的化合物和方法
EP2285819B1 (en)	2008-04-04	2013-10-16	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8679750B2 (en)	2008-05-09	2014-03-25	The University Of British Columbia	Methods and compositions for the treatment of Huntington'S disease
WO2009135322A1 (en)	2008-05-09	2009-11-12	The Universtity Of British Columbia	Methods and compositions for the treatment of huntington's disease
WO2009143391A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc	Methods for modulation expression of creb
WO2009143387A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc.	Modulation of smrt expression
EP2291200A4 (en)	2008-05-22	2012-05-30	Isis Pharmaceuticals Inc	METHODS OF MODULATING EXPRESSION OF RBP4
WO2009148605A2 (en)	2008-06-04	2009-12-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
JP2011526931A (ja)	2008-07-03	2011-10-20	エグゼリクシス，インコーポレイテッド	Ｃｄｋモジュレーター
US8691971B2 (en)	2008-09-23	2014-04-08	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2361256B1 (en)	2008-09-24	2013-04-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
CN102238967A (zh)	2008-10-07	2011-11-09	哈佛大学校长及研究员协会	端粒酶抑制剂及其使用方法
CN104857526B (zh)	2008-10-22	2019-03-05	夸克制药公司	治疗眼部疾病的方法
WO2010048552A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Methods of using oligomeric compounds comprising 2'-substituted nucleosides
CA2744987C (en)	2008-12-02	2018-01-16	Chiralgen, Ltd.	Method for the synthesis of phosphorus atom modified nucleic acids
CN102307889A (zh)	2008-12-23	2012-01-04	集润德斯股份公司	硫化剂及其用于寡核苷酸合成的用途
WO2010080953A1 (en)	2009-01-08	2010-07-15	Isis Pharmaceuticals, Inc.	Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
US20120264806A1 (en)	2009-02-06	2012-10-18	Bennett C Frank	Oligomeric compounds and excipients
MX2011008383A (es)	2009-02-10	2011-09-06	Idera Pharmaceuticals Inc	Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
AU2010221419B2 (en)	2009-03-02	2015-10-01	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
US9107933B2 (en)	2009-03-16	2015-08-18	Isis Pharmaceuticals, Inc.	Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
US8987222B2 (en)	2009-04-08	2015-03-24	University Of Massachusetts	Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
CA2759098A1 (en)	2009-04-14	2010-10-21	Smith Holdings, Llc	Methods and compositions for the treatment of medical conditions involving cellular programming
WO2010129853A2 (en)	2009-05-07	2010-11-11	The Regents Of The University Of California	TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
CA2801178A1 (en)	2009-06-01	2010-12-09	The Regents Of The University Of California	Nucleic acid delivery compositions and methods of use thereof
TWI494125B (zh)	2009-06-05	2015-08-01	Infectious Disease Res Inst	合成的葡萄吡喃糖基脂質佐劑
HUE039741T2 (hu)	2009-06-17	2019-01-28	Biogen Ma Inc	Készítmények és módszerek az SMN2 splicing módosítására egy alanynál
US8329024B2 (en)	2009-07-06	2012-12-11	Ada Technologies, Inc.	Electrochemical device and method for long-term measurement of hypohalites
WO2011005761A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc	Novel nucleic acid prodrugs and methods use thereof
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
US20110009477A1 (en)	2009-07-08	2011-01-13	Idera Pharmaceuticals, Inc.	Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011015573A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en)	2009-08-10	2015-01-06	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides and uses thereof
NZ714887A (en)	2009-09-11	2019-07-26	Ionis Pharmaceuticals Inc	Modulation of huntingtin expression
WO2011034072A1 (ja)	2009-09-16	2011-03-24	株式会社キラルジェン	Rna及びその誘導体合成のための新規保護基
EP2480667A4 (en)	2009-09-25	2013-07-03	Isis Pharmaceuticals Inc	MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
EA201290147A1 (ru)	2009-10-15	2012-11-30	Пфайзер Инк.	Пирроло[2,3-d]пиримидиновые соединения
US8735417B2 (en)	2009-12-17	2014-05-27	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
BR112012016912A2 (pt)	2009-12-28	2016-04-05	Achira Labs Pvt Ltd	composição de gel de diagnóstico, método para preparar uma composição de gel de diagnóstico
WO2011085271A2 (en)	2010-01-08	2011-07-14	Isis Pharmaceuticals, Inc.	Modulation of angiopoietin-like 3 expression
US8750507B2 (en)	2010-01-25	2014-06-10	Cisco Technology, Inc.	Dynamic group creation for managed key servers
US9006198B2 (en)	2010-02-08	2015-04-14	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
WO2011097643A1 (en)	2010-02-08	2011-08-11	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
DK2534149T3 (da)	2010-02-10	2015-01-05	Glaxosmithkline Llc	6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
US8859755B2 (en)	2010-03-05	2014-10-14	Chiralgen, Ltd.	Method for preparing ribonucleoside phosphorothioate
WO2011127175A1 (en)	2010-04-06	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cd130 (gp130) expression
CA2795750A1 (en)	2010-04-07	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cetp expression
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
KR101869570B1 (ko)	2010-04-28	2018-06-20	아이오니스 파마수티컬즈, 인코포레이티드	변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
EP2625186B1 (en)	2010-04-28	2016-07-27	Ionis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
GB201008902D0 (en)	2010-05-27	2010-07-14	Imp Innovations Ltd	Membrane enhanced polymer sythesis
CN103221549A (zh)	2010-08-31	2013-07-24	默沙东公司	用于递送寡核苷酸的新型简单化学实体和方法
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
CN103080314B (zh)	2010-09-30	2016-04-13	Lsip基金运营联合公司	显性突变基因表达抑制剂
KR101381048B1 (ko)	2010-10-20	2014-04-14	씨제이제일제당 (주)	Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
EP3766975A1 (en)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20130289094A1 (en) *	2010-10-29	2013-10-31	Alnylam Pharmaceuticals, Inc.	Compositions and Methods for Inhibition of PCSK9 Genes
EP2638163B1 (en)	2010-11-12	2017-05-17	The General Hospital Corporation	Polycomb-associated non-coding rnas
WO2012073857A1 (ja)	2010-11-30	2012-06-07	株式会社キラルジェン	２'－ｏ－修飾ｒｎａ
WO2012109395A1 (en)	2011-02-08	2012-08-16	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109667A1 (en)	2011-02-12	2012-08-16	University Of Iowa Research Foundation	Therapeutic compounds
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
BR112014001244A2 (pt)	2011-07-19	2017-02-21	Wave Life Sciences Pte Ltd	métodos para a síntese de ácidos nucléicos funcionalizados
DK2742136T3 (da)	2011-08-11	2017-11-20	Ionis Pharmaceuticals Inc	Gapmerforbindelser omfattende 5'-modificerede deoxyribonukleosider i gap og anvendelser deraf
US20140080896A1 (en)	2011-08-30	2014-03-20	The Regents Of The University Of California	Identification of small molecules that facilitate therapeutic exon skipping
US10557136B2 (en)	2011-12-12	2020-02-11	Oncolmmunin Inc.	In vivo delivery of oligonucleotides
CN102675386B (zh)	2011-12-24	2014-07-02	河南科技大学	一种龙胆苦苷分离提纯方法
US8957042B2 (en)	2012-03-07	2015-02-17	The Texas A&M University System	Cancer treatment targeting non-coding RNA overexpression
KR20130114435A (ko)	2012-04-09	2013-10-17	삼성전자주식회사	다수의 전극을 갖는 생분자 검출 장치
IN2014DN10144A (pl)	2012-05-30	2015-08-21	Hokkaido System Science Co Ltd
AU2013289880B2 (en)	2012-07-13	2018-08-02	Wave Life Sciences Ltd.	Chiral control
SG11201500243WA (en)	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
JP6268157B2 (ja)	2012-07-13	2018-01-24	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	不斉補助基
CN104717982B (zh)	2012-08-06	2018-08-28	阿尔尼拉姆医药品有限公司	碳水化合物共轭物及其制备改进工艺
EP2885312A4 (en)	2012-08-15	2016-01-20	Isis Pharmaceuticals Inc	PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS USING MODIFIED STREAMING PROTOCOLS
WO2014059356A2 (en)	2012-10-12	2014-04-17	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
KR20150083920A (ko)	2012-11-15	2015-07-20	로슈 이노베이션 센터 코펜하겐 에이/에스	항 apob 안티센스 접합체 화합물
JP6463687B2 (ja)	2012-11-26	2019-02-06	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	Ｆｇｆｒ３の発現の調節のための組成物及び方法
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
DK2951305T3 (en)	2013-01-30	2018-10-29	Hoffmann La Roche	LNA oligonucleotide KULHYDRATKONJUGATER
CA2899924A1 (en)	2013-02-04	2014-08-07	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
AU2014259750B2 (en)	2013-05-01	2019-02-28	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
WO2014188001A1 (en)	2013-05-24	2014-11-27	Santaris Pharma A/S	Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
WO2014189142A1 (ja)	2013-05-24	2014-11-27	味の素株式会社	モルフォリノオリゴヌクレオチドの製造方法
KR101931089B1 (ko)	2013-06-27	2019-03-14	로슈 이노베이션 센터 코펜하겐 에이/에스	Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
JP6697384B2 (ja)	2013-07-25	2020-05-20	イグジキュア, インコーポレーテッドExicure, Inc.	予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
AU2014329452B2 (en)	2013-10-03	2019-06-20	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
US9988627B2 (en)	2013-10-04	2018-06-05	Novartis Ag	Formats for organic compounds for use in RNA interference
JP2016537341A (ja)	2013-11-11	2016-12-01	サンガモバイオサイエンシーズ，インコーポレイテッド	ハンチントン病を処置するための方法および組成物
EP3068885A1 (en)	2013-11-14	2016-09-21	Roche Innovation Center Copenhagen A/S	Apob antisense conjugate compounds
EP2918275B1 (en)	2013-12-13	2016-05-18	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en)	2014-01-15	2018-12-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
DK3094728T3 (da)	2014-01-16	2022-05-16	Wave Life Sciences Ltd	Kiralt design
DK3137476T3 (da)	2014-04-28	2019-11-18	Ionis Pharmaceuticals Inc	Linker-modificerede oligomerforbindelser
MX2016014102A (es)	2014-05-01	2017-05-03	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
RU2691102C2 (ru)	2014-05-08	2019-06-11	Сангамо Байосайенсиз, Инк.	Способы и композиции для лечения болезни хантингтона
AU2015264263B2 (en)	2014-05-20	2021-08-05	University Of Iowa Research Foundation	Huntington's disease therapeutic compounds
US20160017327A1 (en)	2014-07-11	2016-01-21	The Johns Hopkins University	Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
WO2016011226A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP2982758A1 (en)	2014-08-04	2016-02-10	Centre Hospitalier Universitaire Vaudois (CHUV)	Genome editing for the treatment of huntington's disease
NZ730296A (en)	2014-08-20	2023-09-29	Alnylam Pharmaceuticals Inc	Modified double-stranded rna agents
WO2016027168A2 (en)	2014-08-20	2016-02-25	Lifesplice Pharma Llc	Splice modulating oligonucleotides and methods of use thereof
WO2016037191A1 (en)	2014-09-05	2016-03-10	Health Research, Inc.	Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
JP2017536366A (ja)	2014-11-19	2017-12-07	ロシュイノベーションセンターコペンハーゲンエーエス	Ｌｎａキラルホスホロチオエート
US10815481B2 (en)	2014-12-16	2020-10-27	Roche Innovation Center Copenhagen A/S	Chiral library screen
LT3237618T (lt)	2014-12-24	2019-07-10	Uniqure Ip B.V.	Rnri sukeltas hantingtino geno slopinimas
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
CN115181778A (zh)	2015-02-04	2022-10-14	百时美施贵宝公司	选择治疗性分子的方法
WO2016127002A1 (en)	2015-02-04	2016-08-11	Bristol-Myers Squibb Company	Lna oligonucleotides with alternating flanks
JP2018506304A (ja)	2015-02-10	2018-03-08	ジェンザイム・コーポレーション	バリアントＲＮＡｉ
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262174A4 (en)	2015-02-23	2018-10-17	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing antisense activity
WO2016141236A1 (en)	2015-03-03	2016-09-09	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
WO2016154096A1 (en)	2015-03-20	2016-09-29	Ionis Pharmaceuticals, Inc.	Modulation of smggds expression
LT3277814T (lt)	2015-04-03	2020-10-26	University Of Massachusetts	Oligonukleotidų junginiai, skirti nukreipimui į hantingtino mrnr
US10851371B2 (en)	2015-04-10	2020-12-01	Ionis Pharmaceuticals, Inc.	Modulation of SMN expression
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2017004261A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
EP4092119A3 (en)	2015-07-10	2023-03-22	Ionis Pharmaceuticals, Inc.	Modulators of diacyglycerol acyltransferase 2 (dgat2)
DK3324980T3 (da)	2015-07-17	2022-02-14	Alnylam Pharmaceuticals Inc	Multimålrettede enkeltenhedskonjugater
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
US20180216114A1 (en)	2015-07-27	2018-08-02	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
IL296476B1 (en)	2015-07-31	2024-06-01	Alnylam Pharmaceuticals Inc	Preparations of transthyretin (TTR) iRNA and methods of using them for the treatment or prevention of TTR-related diseases
DK3341479T3 (da)	2015-08-24	2020-02-24	Roche Innovation Ct Copenhagen As	LNA-G-Proces
IL257486B (en)	2015-08-25	2022-07-01	Alnylam Pharmaceuticals Inc	Methods and preparations for treating disorders related to the pcsk9 gene
JP7028764B2 (ja)	2015-09-02	2022-03-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	プログラム細胞死１リガンド１（ＰＤ－Ｌ１）ｉＲＮＡ組成物およびその使用方法
US10577388B2 (en)	2015-10-02	2020-03-03	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugation process
WO2017062862A2 (en)	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
EP3394258B1 (en)	2015-10-22	2021-09-22	Roche Innovation Center Copenhagen A/S	In vitro toxicity screening assay
JP2018533362A (ja)	2015-11-12	2018-11-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	薬物候補の有効性プロファイルを決定するための方法
AU2017234150B2 (en)	2016-03-13	2021-09-16	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
PE20181892A1 (es)	2016-03-14	2018-12-11	Hoffmann La Roche	Oligonucleotidos para reducir la expresion de pd-l1
WO2017157672A1 (en)	2016-03-18	2017-09-21	Roche Innovation Center Copenhagen A/S	Acyl-protected l-lna-guanosine monomers
CN109153697A (zh)	2016-04-14	2019-01-04	豪夫迈·罗氏有限公司	三苯甲基-单-GalNAc化合物及其用途
MA45290A (fr)	2016-05-04	2019-03-13	Wave Life Sciences Ltd	Procédés et compositions d'agents biologiquement actifs
MA45270A (fr)	2016-05-04	2017-11-09	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
DK3455232T3 (da)	2016-05-12	2020-07-06	Roche Innovation Ct Copenhagen As	Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
JP7083756B2 (ja)	2016-05-13	2022-06-13	エフ．ホフマン－ラロシュアーゲー	タンパク質系試料回収マトリックス及び装置
JP2019520339A (ja)	2016-06-03	2019-07-18	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド、その組成物および方法
US20190264267A1 (en)	2016-07-25	2019-08-29	Wave Life Sciences Ltd.	Phasing
MA46905A (fr)	2016-11-23	2019-10-02	Wave Life Sciences Ltd	Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
WO2018223073A1 (en)	2017-06-02	2018-12-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP2020524485A (ja)	2017-06-02	2020-08-20	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
US11603532B2 (en)	2017-06-02	2023-03-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP7402696B2 (ja)	2017-06-21	2023-12-21	ウェイブライフサイエンシズリミテッド	合成のための化合物、組成物、及び方法
US11814407B2 (en)	2017-06-28	2023-11-14	Roche Innovation Center Copenhagen A/S	Multiple coupling and oxidation method
CA3072076A1 (en)	2017-08-08	2019-02-14	Chandra Vargeese	Oligonucleotide compositions and methods thereof
SG11202000276YA (en)	2017-09-18	2020-04-29	Wave Life Sciences Ltd	Technologies for oligonucleotide preparation
JP2020537518A (ja)	2017-10-12	2020-12-24	ウェーブライフサイエンシーズリミテッド	オリゴヌクレオチド組成物及びその方法
EP3728281A1 (en)	2017-12-21	2020-10-28	Alnylam Pharmaceuticals Inc.	Chirally-enriched double-stranded rna agents
SG11202009877XA (en)	2018-04-12	2020-11-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
JP7427608B2 (ja)	2018-05-11	2024-02-05	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその使用方法
AU2019392928A1 (en)	2018-12-06	2021-06-17	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
KR20210121199A (ko)	2019-02-01	2021-10-07	웨이브 라이프 사이언시스 리미티드	올리고뉴클레오티드 조성물 및 이의 방법
FR3093595B1 (fr)	2019-03-07	2022-03-11	Thales Sa	Systeme de calibration depuis le sol d'une charge utile d'un satellite
EP3941924A4 (en)	2019-03-20	2022-12-28	Wave Life Sciences Ltd.	USEFUL TECHNOLOGIES FOR THE PREPARATION OF OLIGONUCLEOTIDES
JPWO2020196662A1 (pl)	2019-03-25	2020-10-01
MX2021012862A (es)	2019-04-25	2022-03-04	Wave Life Sciences Ltd	Composiciones de oligonucleotidos y metodos de uso de las mismas.
US20230145795A1 (en)	2019-04-25	2023-05-11	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP2022532169A (ja)	2019-05-09	2022-07-13	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその使用方法
CN114585737A (zh)	2019-10-06	2022-06-03	波涛生命科学有限公司	寡核苷酸组合物及其使用方法
US20240175016A1 (en)	2019-10-06	2024-05-30	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
AU2021230473A1 (en)	2020-03-01	2022-09-22	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP4153604A1 (en)	2020-05-22	2023-03-29	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof

2013
- 2013-07-12 AU AU2013289880A patent/AU2013289880B2/en active Active
- 2013-07-12 SG SG10201912895PA patent/SG10201912895PA/en unknown
- 2013-07-12 RU RU2015104762A patent/RU2015104762A/ru not_active Application Discontinuation
- 2013-07-12 SG SG11201500232UA patent/SG11201500232UA/en unknown
- 2013-07-12 KR KR1020217003318A patent/KR102450907B1/ko active IP Right Grant
- 2013-07-12 JP JP2015521874A patent/JP6453212B2/ja active Active
- 2013-07-12 CN CN201380047876.5A patent/CN104661664B/zh active Active
- 2013-07-12 EP EP13817244.0A patent/EP2872147B1/en active Active
- 2013-07-12 MX MX2015000577A patent/MX2015000577A/es unknown
- 2013-07-12 DK DK13817244.0T patent/DK2872147T3/da active
- 2013-07-12 PL PL13817244.0T patent/PL2872147T3/pl unknown
- 2013-07-12 CN CN202010516947.3A patent/CN112007045A/zh active Pending
- 2013-07-12 CA CA2878945A patent/CA2878945A1/en active Pending
- 2013-07-12 US US14/414,614 patent/US9982257B2/en active Active
- 2013-07-12 WO PCT/US2013/050407 patent/WO2014012081A2/en active Application Filing
- 2013-07-12 KR KR1020227034058A patent/KR20220139425A/ko not_active Application Discontinuation
- 2013-07-12 ES ES13817244T patent/ES2940887T3/es active Active
- 2013-07-12 KR KR1020157003995A patent/KR102213609B1/ko active IP Right Grant
- 2013-07-12 SG SG10201700283WA patent/SG10201700283WA/en unknown
- 2013-07-12 EP EP22215059.1A patent/EP4219516A3/en active Pending
2015
- 2015-01-11 IL IL236621A patent/IL236621B/en active IP Right Grant
- 2015-01-13 CL CL2015000092A patent/CL2015000092A1/es unknown
- 2015-11-18 HK HK15111363.9A patent/HK1210595A1/xx unknown
2017
- 2017-03-17 US US15/462,787 patent/US10590413B2/en active Active
2018
- 2018-07-13 AU AU2018205183A patent/AU2018205183B2/en active Active
- 2018-12-12 JP JP2018233004A patent/JP7004637B2/ja active Active
2019
- 2019-12-17 US US16/717,986 patent/US11643657B2/en active Active
2020
- 2020-10-01 AU AU2020244546A patent/AU2020244546B2/en active Active
2022
- 2022-01-04 JP JP2022000295A patent/JP2022050518A/ja active Pending
- 2022-12-19 AU AU2022291426A patent/AU2022291426A1/en active Pending
2023
- 2023-05-05 US US18/313,032 patent/US20240229026A1/en active Pending

Also Published As

Publication number	Publication date
HK1210595A1 (en)	2016-04-29
IL236621A0 (en)	2015-02-26
MX2015000577A (es)	2015-08-14
AU2022291426A1 (en)	2023-02-02
EP4219516A2 (en)	2023-08-02
US20150211006A1 (en)	2015-07-30
KR20150036642A (ko)	2015-04-07
AU2013289880B2 (en)	2018-08-02
KR102450907B1 (ko)	2022-10-04
AU2018205183A1 (en)	2018-08-02
EP2872147B1 (en)	2022-12-21
WO2014012081A2 (en)	2014-01-16
CA2878945A1 (en)	2014-01-16
JP7004637B2 (ja)	2022-02-04
WO2014012081A3 (en)	2014-03-06
KR102213609B1 (ko)	2021-02-08
SG10201700283WA (en)	2017-03-30
KR20220139425A (ko)	2022-10-14
AU2020244546A1 (en)	2020-10-29
US10590413B2 (en)	2020-03-17
US9982257B2 (en)	2018-05-29
US20210130821A1 (en)	2021-05-06
AU2020244546B2 (en)	2022-09-22
CL2015000092A1 (es)	2015-08-07
IL236621B (en)	2019-12-31
AU2013289880A1 (en)	2015-02-05
DK2872147T3 (da)	2023-02-20
SG11201500232UA (en)	2015-04-29
EP2872147A2 (en)	2015-05-20
CN104661664B (zh)	2020-07-03
ES2940887T3 (es)	2023-05-12
CN112007045A (zh)	2020-12-01
EP2872147A4 (en)	2016-01-20
CN104661664A (zh)	2015-05-27
SG10201912895PA (en)	2020-02-27
JP2022050518A (ja)	2022-03-30
AU2018205183B2 (en)	2020-07-02
US20240229026A1 (en)	2024-07-11
RU2015104762A3 (pl)	2018-08-31
JP6453212B2 (ja)	2019-01-16
EP4219516A3 (en)	2024-01-10
RU2015104762A (ru)	2018-08-31
JP2019069971A (ja)	2019-05-09
US20170275621A1 (en)	2017-09-28
KR20210016078A (ko)	2021-02-10
US11643657B2 (en)	2023-05-09
JP2015528002A (ja)	2015-09-24

Publication	Publication Date	Title
PL2872147T3 (pl)	2023-09-25	Sposób wytwarzania chiralnych oligonukleotydów
ZA201501833B (en)	2016-08-31	Method for obtaining 1-kestone
EP2913831A4 (en)	2015-11-25	PROCESS FOR PRODUCING RARE EARTH MAGNET
GB201212937D0 (en)	2012-09-05	Method
GB201212932D0 (en)	2012-09-05	Method
GB201213636D0 (en)	2012-09-12	Method
EP2938814A4 (en)	2016-07-13	METHOD FOR PRODUCING OIL
SG11201404201XA (en)	2014-09-26	Production method for polyamide
EP2821392A4 (en)	2015-04-08	PROCESS FOR THE PREPARATION OF ACRYLNITRILE
GB201212934D0 (en)	2012-09-05	Method
GB201210858D0 (en)	2012-08-01	Method
EP2903007A4 (en)	2016-07-20	METHOD FOR PRODUCING A PATTERN
LT2852602T (lt)	2020-10-26	Oligonukleotidų konjugavimo būdas
EP2837619A4 (en)	2015-11-11	PROCESS FOR THE PRODUCTION OF BETA-ALCOXYPROPIONAMIDE
IL238755B (en)	2018-03-29	A method for the production of carboxamides
EP2880048A4 (en)	2016-05-25	METHOD
EP2837598A4 (en)	2015-12-23	PROCESS FOR PRODUCING ALUMINA
EP2824130A4 (en)	2015-10-14	PROCESS FOR PRODUCING POLYDIALKYLSILANE
GB201202198D0 (en)	2012-03-21	Method
EP2871155A4 (en)	2016-03-30	PROCESS FOR PRODUCING POLYSILICON
EP2803732A4 (en)	2015-08-26	PROCESS FOR PREPARING A CHEMICAL FABRIC
SG11201501567QA (en)	2015-04-29	Method for producing 7-octenal
EP2803730A4 (en)	2015-08-26	PROCESS FOR PREPARING A CHEMICAL SUBSTANCE
GB201211393D0 (en)	2012-08-08	Method
SG11201503452YA (en)	2015-06-29	Method for producing polyamide